Changes in Biomarkers Using Prostaglandin Inhibitors
NCT01769625
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Biomarker Change Linked to Breast Cancer
Interventions
DRUG:
placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Sponsor
Hartford Hospital
Collaborators
[object Object]